233 related articles for article (PubMed ID: 11332334)
1. The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertension.
Himmelmann A; Keinänen-Kiukaanniemi S; Wester A; Redón J; Asmar R; Hedner T;
Blood Press; 2001; 10(1):43-51. PubMed ID: 11332334
[TBL] [Abstract][Full Text] [Related]
2. Candesartan cilexetil: comparison of once-daily versus twice-daily administration for systemic hypertension. Candesartan Cilexetil Study Investigators.
Zuschke CA; Keys I; Munger MA; Carr AA; Marinides GN; Flanagan TL; Cushing DJ; Hayes JL; Michelson EL
Clin Ther; 1999 Mar; 21(3):464-74. PubMed ID: 10321416
[TBL] [Abstract][Full Text] [Related]
3. A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring.
Baguet JP; Nisse-Durgeat S; Mouret S; Asmar R; Mallion JM
Int J Clin Pract; 2006 Apr; 60(4):391-8. PubMed ID: 16620350
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of a combination tablet of candesartan cilexetil and hydrochlorothiazide in insufficiently controlled primary hypertension--comparison with a combination of losartan and hydrochlorothiazide.
Ohma KP; Milon H; Valnes K
Blood Press; 2000; 9(4):214-20. PubMed ID: 11055474
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the AT1-receptor blocker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patients.
McInnes GT; O'Kane KP; Istad H; Keinänen-Kiukaanniemi S; Van Mierlo HF
J Hum Hypertens; 2000 Apr; 14(4):263-9. PubMed ID: 10805052
[TBL] [Abstract][Full Text] [Related]
6. A new approach to assessing antihypertensive therapy: effect of treatment on pulse pressure. Candesartan cilexetil in Hypertension Ambulatory Measurement of Blood Pressure (CHAMP) Study Investigators.
Asmar R; Lacourcière Y
J Hypertens; 2000 Nov; 18(11):1683-90. PubMed ID: 11081784
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide.
Malmqvist K; Kahan T; Dahl M
Am J Hypertens; 2000 May; 13(5 Pt 1):504-11. PubMed ID: 10826401
[TBL] [Abstract][Full Text] [Related]
8. Comparison of candesartan versus enalapril in essential hypertension. Italian Candesartan Study Group.
Zanchetti A; Omboni S
Am J Hypertens; 2001 Feb; 14(2):129-34. PubMed ID: 11243303
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy and tolerability of candesartan cilexetil. Candesartan Study Groups in Japan.
Ogihara T; Arakawa K
J Hum Hypertens; 1999 Jan; 13 Suppl 1():S27-31; discussion S33-4. PubMed ID: 10076918
[TBL] [Abstract][Full Text] [Related]
10. Clinical profile of the novel angiotensin II type I blocker candesartan cilexetil.
Sever PS
J Hypertens Suppl; 1997 Dec; 15(6):S9-12. PubMed ID: 9493121
[TBL] [Abstract][Full Text] [Related]
11. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/Losartan study investigators.
Lacourcière Y; Asmar R
Am J Hypertens; 1999 Dec; 12(12 Pt 1-2):1181-7. PubMed ID: 10619580
[TBL] [Abstract][Full Text] [Related]
12. Effects of candesartan cilexetil in patients with severe systemic hypertension. Candesartan Cilexetil Study Investigators.
Oparil S; Levine JH; Zuschke CA; Gradman AH; Ripley E; Jones DW; Hardison JD; Cushing DJ; Prasad R; Michelson EL
Am J Cardiol; 1999 Aug; 84(3):289-93. PubMed ID: 10496437
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
Rakugi H; Ogihara T; Miyata Y; Sasai K; Totsuka N
Clin Ther; 2012 Apr; 34(4):838-48. PubMed ID: 22440192
[TBL] [Abstract][Full Text] [Related]
14. A multicentre, 12-week study of imidapril and candesartan cilexetil in patients with mild to moderate hypertension using ambulatory blood pressure monitoring.
Palma-Gamiz JL; Pêgo M; Marquez E; Pujol M; Olivan J; Alegría E; Sagastagoitia-Gorostiza JD; Gonzalez-Juanatey JR
Clin Drug Investig; 2007; 27(6):407-17. PubMed ID: 17506591
[TBL] [Abstract][Full Text] [Related]
15. Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators.
Kloner RA; Weinberger M; Pool JL; Chrysant SG; Prasad R; Harris SM; Zyczynski TM; Leidy NK; Michelson EL;
Am J Cardiol; 2001 Mar; 87(6):727-31. PubMed ID: 11249891
[TBL] [Abstract][Full Text] [Related]
16. A forced titration study of antihypertensive efficacy of candesartan cilexetil in comparison to losartan: CLAIM Study II.
Vidt DG; White WB; Ridley E; Rahman M; Harris S; Vendetti J; Michelson EL; Wang R;
J Hum Hypertens; 2001 Jul; 15(7):475-80. PubMed ID: 11464257
[TBL] [Abstract][Full Text] [Related]
17. Effects of candesartan cilexetil in patients with systemic hypertension. Candesartan Cilexetil Study Investigators.
Reif M; White WB; Fagan TC; Oparil S; Flanagan TL; Edwards DT; Cushing DJ; Michelson EL
Am J Cardiol; 1998 Oct; 82(8):961-5. PubMed ID: 9794352
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with candesartan cilexetil 32 mg and hydrochlorothiazide 25 mg provides the full additive antihypertensive effect of the components: A randomized, double-blind, parallel-group study in primary care.
Edes I;
Clin Drug Investig; 2009; 29(5):293-304. PubMed ID: 19366271
[TBL] [Abstract][Full Text] [Related]
19. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study.
Cuspidi C; Muiesan ML; Valagussa L; Salvetti M; Di Biagio C; Agabiti-Rosei E; Magnani B; Zanchetti A;
J Hypertens; 2002 Nov; 20(11):2293-300. PubMed ID: 12409969
[TBL] [Abstract][Full Text] [Related]
20. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan.
Andersson OK; Neldam S
Blood Press; 1998 Jan; 7(1):53-9. PubMed ID: 9551878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
